Anti-cataract agent discovered

Article

An investigation, published in Inorganic Chemistry, has revealed that the reaction of pirenoxine (PRX) with selenite or calcium ions could be adapted as an anti-cataract agent.

An investigation, published in Inorganic Chemistry, has revealed that the reaction of pirenoxine (PRX) with selenite or calcium ions could be adapted as an anti-cataract agent. Seleneite and calcium ions have been associated with the formation of lens cataracts.

Dr Jiahn-Haur Liao, Institute of Biological Chemistry, Academia Sinica, Taiwan, ld the study that found theoretical evidence that the interactions most likely occur at the bezoquinone (ring I) π-system.

Isothermal titration calorimetry (ITC), UV and Nuclear magnetic resonance spectroscopy (NMR) were used to demonstrate that PRX can bind a maximum of six selenite anions.

Peripheral binding occurred first and was followed by the π−π interactions with the aromatic moiety. The calcium ions were chelated by the 3-carboxylate and 8-ketomine functional groups for calcium cation interaction.

The results could provide the foundation for further studies involving the use PRX as an anti-cataract agent.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.